[go: up one dir, main page]

BRPI0407300A - Uses of a functional hsgk1 protein or hsgk3 protein inhibitor or negative transcription regulator of the hsgk1 gene or hsgk3 gene, a single stranded or double stranded nucleic acid, and an antibody, drug, diagnostic kit, and, screening method for identifying and characterizing therapeutically active substances - Google Patents

Uses of a functional hsgk1 protein or hsgk3 protein inhibitor or negative transcription regulator of the hsgk1 gene or hsgk3 gene, a single stranded or double stranded nucleic acid, and an antibody, drug, diagnostic kit, and, screening method for identifying and characterizing therapeutically active substances

Info

Publication number
BRPI0407300A
BRPI0407300A BR0407300-2A BRPI0407300A BRPI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A BR PI0407300 A BRPI0407300 A BR PI0407300A
Authority
BR
Brazil
Prior art keywords
hsgk1
hsgk3
gene
protein
nucleic acid
Prior art date
Application number
BR0407300-2A
Other languages
Portuguese (pt)
Inventor
Florian Lang
Original Assignee
Florian Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang filed Critical Florian Lang
Publication of BRPI0407300A publication Critical patent/BRPI0407300A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/166—Cataract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"USOS DE UM INIBIDOR FUNCIONAL DA PROTEìNA HSGK1 OU DA PROTEìNA HSGK3 OU DE UM REGULADOR NEGATIVO DA TRANSCRIçãO DO GENE HSGK1 OU DO GENE HSGK3, DE UM áCIDO NUCLEICO DE FILAMENTO úNICO OU FILAMENTO DUPLO E DE UM ANTICORPO, FáRMACO, KIT PARA DIAGNóSTICO, E, MéTODO DE TRIAGEM PARA IDENTIFICAR E CARACTERIZAR SUBSTâNCIAS TERAPEUTICAMENTE ATIVAS". A invenção refere-se ao uso de um inibidor funcional de proteína hsgk1 ou hsgk3 ou um regulador de transcrição negativo de gene hsgk1 ou hsgk3 na produção de um medicamento para o tratamento e/ou profilaxia de uma catarata, glaucoma ou neuropatia diabética. Outro aspecto da invenção refere-se ao uso de um ácido nucleico de filamento único ou filamento duplo compreendendo a seq³ência hsgk1 de acordo com número de acesso NM005627 ou um dos fragmentos dos mesmos ou compreendendo a seq³ência hsgk3 de acordo com número de acesso AFI69035 ou um dos fragmentos dos mesmos no diagnóstico de uma predisposição à formação de uma catarata, glaucoma e/ou neuropatia diabética, além de um kit para diagnóstico de uma predisposição à formação de uma catarata, glaucoma e/ou neuropatia diabética, compreendendo o ácido nucleico acima mencionado. A invenção ainda refere-se a vários métodos de triagem para a identificação e caracterização de substâncias terapeuticamente eficazes dentre uma pluralidade de substâncias de teste para o tratamento e/ou profilaxia de, pelo menos, uma doença selecionada dentre catarata, glaucoma ou neuropatia diabética."USES OF A FUNCTIONAL INHIBITOR OF HSGK1 PROTEIN OR HSGK3 PROTEIN OR NEGATIVE TRANSCRIPTION REGULATOR OF HSGK1 GENE OR HSGK3 GENE, SINGLE FILTRA NUCLEIC ACID AND K, PHYDROMIC, FRAMOS, AND DIAGNOSTIC ANTIBODY , METHOD OF TRIALING TO IDENTIFY AND CHARACTERIZE THERAPEUTICALLY ACTIVE SUBSTANCES ". The invention relates to the use of a functional hsgk1 or hsgk3 protein inhibitor or a hsgk1 or hsgk3 negative transcriptional regulator in the manufacture of a medicament for the treatment and / or prophylaxis of a cataract, glaucoma or diabetic neuropathy. Another aspect of the invention relates to the use of a single stranded or double stranded nucleic acid comprising the sequence hsgk1 according to accession number NM005627 or one of the fragments thereof or comprising the sequence hsgk3 according to accession number AFI69035 or a fragments thereof in the diagnosis of a predisposition to the formation of a cataract, glaucoma and / or diabetic neuropathy, and a kit for diagnosing a predisposition to the formation of a cataract, glaucoma and / or diabetic neuropathy, comprising the aforementioned nucleic acid . The invention further relates to various screening methods for the identification and characterization of therapeutically effective substances from a plurality of test substances for the treatment and / or prophylaxis of at least one disease selected from cataract, glaucoma or diabetic neuropathy.

BR0407300-2A 2003-02-07 2004-02-05 Uses of a functional hsgk1 protein or hsgk3 protein inhibitor or negative transcription regulator of the hsgk1 gene or hsgk3 gene, a single stranded or double stranded nucleic acid, and an antibody, drug, diagnostic kit, and, screening method for identifying and characterizing therapeutically active substances BRPI0407300A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (en) 2003-02-07 2003-02-07 Use of the sgk gene family for the diagnosis and therapy of cataracts and glaucoma
PCT/EP2004/001048 WO2004069258A2 (en) 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma

Publications (1)

Publication Number Publication Date
BRPI0407300A true BRPI0407300A (en) 2006-02-07

Family

ID=32730900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407300-2A BRPI0407300A (en) 2003-02-07 2004-02-05 Uses of a functional hsgk1 protein or hsgk3 protein inhibitor or negative transcription regulator of the hsgk1 gene or hsgk3 gene, a single stranded or double stranded nucleic acid, and an antibody, drug, diagnostic kit, and, screening method for identifying and characterizing therapeutically active substances

Country Status (13)

Country Link
EP (1) EP1663246A2 (en)
JP (1) JP2006519189A (en)
KR (1) KR20050114214A (en)
CN (1) CN1771039A (en)
AU (1) AU2004210416A1 (en)
BR (1) BRPI0407300A (en)
CA (1) CA2514703A1 (en)
DE (1) DE10305212A1 (en)
MX (1) MXPA05008394A (en)
PL (1) PL378399A1 (en)
RU (1) RU2005127808A (en)
WO (1) WO2004069258A2 (en)
ZA (1) ZA200506280B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007529423A (en) * 2004-03-11 2007-10-25 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Methods for modulating glutamate receptors for the treatment of neuropsychiatric disorders, including the use of modulators of serum and glucocorticoid-inducible kinases
BRPI0508350A (en) * 2004-03-11 2007-07-24 Merck Patent Gmbh methods to interfere with fibrosis
DE102004059781A1 (en) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Use of serum / glucocorticoid-regulated kinase
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
WO2007037560A1 (en) * 2005-09-30 2007-04-05 Link Genomics, Inc. Therapeutic or diagnostic application of sgk2 gene
CA2630668C (en) * 2005-11-22 2016-07-12 Mcgill University Intraocular pressure-regulated early genes and uses thereof
US20080153903A1 (en) * 2006-12-22 2008-06-26 Alcon Manufacturing, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
US9012161B2 (en) * 2011-01-25 2015-04-21 Monell Chemical Senses Center Methods of identifying molecules that provide or enhance sweet taste
KR102357260B1 (en) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 Method for diagnosis and predict of diabetic neuropathy using micro-rna and kit therefor
CN119303113A (en) * 2024-09-03 2025-01-14 河北大学附属医院 Application of NEDD4L gene in the preparation of drugs for the treatment of vascular endothelial cell proliferation-related diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508575A (en) * 1994-08-30 1998-08-25 ユニバーシティ オブ ダンディー Apoptosis inducer and application of the inducer in therapy
WO1996041013A1 (en) * 1995-06-07 1996-12-19 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE19708173A1 (en) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Cell volume regulated human kinase h-sgk
WO1999059559A1 (en) * 1998-05-15 1999-11-25 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
JP2002533063A (en) * 1998-12-14 2002-10-08 ザ、ユニバーシティー、オブ、ダンディー Method
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
DE19917990A1 (en) * 1999-04-20 2000-11-02 Florian Lang Medicament containing inhibitors of cell volume regulated human kinase h-sgk
AU5840300A (en) * 1999-07-14 2001-01-30 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US6416759B1 (en) * 1999-09-30 2002-07-09 The Regents Of The University Of California Antiproliferative Sgk reagents and methods
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10225844A1 (en) * 2002-06-04 2003-12-18 Lang Florian sgk and nedd as diagnostic and therapeutic targets

Also Published As

Publication number Publication date
DE10305212A1 (en) 2004-08-19
RU2005127808A (en) 2006-05-27
EP1663246A2 (en) 2006-06-07
MXPA05008394A (en) 2005-10-05
ZA200506280B (en) 2006-05-31
KR20050114214A (en) 2005-12-05
WO2004069258A3 (en) 2005-02-24
CN1771039A (en) 2006-05-10
WO2004069258A2 (en) 2004-08-19
AU2004210416A1 (en) 2004-08-19
JP2006519189A (en) 2006-08-24
CA2514703A1 (en) 2004-08-19
PL378399A1 (en) 2006-04-03

Similar Documents

Publication Publication Date Title
Tanaka et al. Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system
Alward et al. Variations in the myocilin gene in patients with open-angle glaucoma
Cramer et al. Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease
Garweg et al. Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma
Igarashi et al. Aqueous autotaxin and TGF-βs are promising diagnostic biomarkers for distinguishing open-angle glaucoma subtypes
WO2017106363A1 (en) Refining diagnosis and treatment of complex multi-symptom neurological disorders
WO2015153864A2 (en) Methods for treating inflammatory conditions
BRPI0407300A (en) Uses of a functional hsgk1 protein or hsgk3 protein inhibitor or negative transcription regulator of the hsgk1 gene or hsgk3 gene, a single stranded or double stranded nucleic acid, and an antibody, drug, diagnostic kit, and, screening method for identifying and characterizing therapeutically active substances
Rasmussen et al. Impulsivity in hoarding
Lynch et al. Plasma biomarkers of reticular pseudodrusen and the risk of progression to advanced age-related macular degeneration
Garweg et al. Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment
Khawaja et al. Potential for collider bias in studies examining the association of central corneal thickness with glaucoma
Gerace et al. The gliadin peptide 31-43 exacerbates kainate neurotoxicity in epilepsy models
Xu et al. The TRPV4-YAP axis mediates cytoskeletal and extracellular matrix remodeling in trabecular meshwork cells as a novel glaucoma mechanism
US20150301049A1 (en) Method for diagnosing and treating kidney injury or disease
KR102411176B1 (en) Biomarker composition for diagnosing Deafness comprising SLC4A5 and use thereof
SE0002189D0 (en) New method and assay
Bharwani et al. Serum Soluble Interleukin‐2 Receptor Does Not Differentiate Complex Regional Pain Syndrome from Other Pain Conditions in a Tertiary Referral Setting
WO2017175181A1 (en) Angiogenin as a diagnostic or prognostic biomarker and drug target in age-related macular degeneration
DE502004012230D1 (en) METHOD FOR THE DIAGNOSIS OF ILLNESSES DETERMINED BY APOLIPOPROTEIN C-I
Sun et al. Cardiac remodeling pathways do not accelerate disease onset and severity in a mouse model of PLN-R14del cardiomyopathy
Picciani et al. Potential for transcriptional upregulation of cochlin in glaucomatous trabecular meshwork: a combinatorial bioinformatic and biochemical analytical approach
US20240036064A1 (en) Methods and compositions for detecting cognitive disorder
Lozano et al. Profiling IOP-responsive genes in anterior and posterior ocular tissues in the rat CEI glaucoma model
Wijesundara et al. Comparison of serum oxidative stress, antioxidant parameters and vitamin D levels of Sri Lankan patients with multiple sclerosis and neuromyelitis optica: A pilot study

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.